Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588263 | 1.00 | TAAR1 (0.43) | TAAR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL29589340 | 1.00 | TAAR1 (0.43) | TAAR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL23323076 | 1.00 | TAAR1 (0.43) | TAAR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL23057911 | 1.00 | TAAR1 (0.43) | TAAR1MEN1KMT2ACHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL23064486 | 0.98 | TAAR1 (0.43) | TAAR1MEN1KMT2ACHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL28521128 | 0.98 | TAAR1 (0.43) | TAAR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL19171120 | 0.95 | MEN1 (0.41) | TAAR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL21566690 | 0.95 | MEN1 (0.41) | TAAR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL25243180 | 0.95 | MEN1 (0.41) | TAAR1MEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL3088979 | 0.87 | TAAR1 (0.42) | TAAR1MEN1KMT2ACHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023104043-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | 杭州和正医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2022089463-A1 | BCL-2 PROTEIN APOPTOSIS-INDUCING AGENT AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2022-05-05 | — | — | WO | disclosed |
| WO-2021083135-A1 | Bcl-2 INHIBITORS | BEIGENE, LTD. (KY) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | TAAR1 1800/4885MEN1 3960/4885KMT2A 2454/4885 |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | TAAR1 4675/4885MEN1 3803/4885KMT2A 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.